Get Flat 20% Discount on All Medications
  • Danielle Jolla, United States says, "I love your online pharmacy Because of your quick shipping and reasonable prices."
  • Jill Barrella, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "I am very satisfied with IDM and plan on making more purchases in the future. IDMs prices are low which makes it very compelling to use over conventional pharmacies with high copays and more restrictions continually implemented."
  • Eric Gonzales, United States says, "The website is very user friendly, there is a lot of variety and checking out was easy."
  • Albert Martinez, United States says, "Very organized and efficient concerning delivery and products are great. Very satisfied, impressed with delivery and product."
  • Natalie Wallace, United States says, "I absolutely love getting my medications at a great price and I always get that here. And I recommend this site to my family and friends."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @
    Get your instant Coupon now!
    Price challenge
    You can find the latest happening of our pharmacy Visit to discuss on various diseases and conditions
    Follow us on Twitter

      Almirall gets FDA approval for migraine drug


      MADRID, June 3 (Reuters) - Spanish pharmaceutical firm Almirall (ALM.MC: Quote, Profile, Research, Stock Buzz) on Wednesday said its Almotriptan migraine drug had gained U.S. Food and Drug Administration approval for adolescents.

      The drug -- marketed with U.S. partner Johnson & Johnson's (JNJ.N: Quote, Profile, Research, Stock Buzz) Ortho-McNeil Janssen Pharmaceuticals -- was already sold to treat migraines in adults, but is the first of its kind to be approved by the FDA for adolescents, Almirall said.

      "This is a huge step for Almirall and our North American partner as it shows our commitment to giving adolescents with migraines a treatment that has not existed to date," it said.

      Almirall's patent on Almotriptan in the United States has been extended to November 2015.

      June 04, 2009


      Share this Article!

    Back to top^